We propose to develop analogs of human complement C3 that have the ability to form a stable C3 convertase. In addition, these proteins will be designed to decrease the affinity of the proteins for factor H binding. All proteins will be expressed in the Baculovirus insect protein expression system, and tested for their ability to form a stable C3 convertase enzyme that is able to deplete complement in human serum. They will also be tested for their resistance to cleavage by complement factors H and I. Proteins that can form stable and active C3 convertases that are resistant to cleavage by complement factors H and I will be tested in in vitro pharmacokinetics, stability, and aggregation studies. In Phase II of this application, we will test these proteins for their ability to protect PNH erythrocytes against lysis, and in animal models. We will also commence GMP production of the protein and initiate IND-enabling development, including preclinical immunogenicity assessment, to prepare for Phase I clinical trials.
The complement arm of the innate immune system is implicated in paroxysmal nocturnal hemoglobinuria (PNH). This project will create and test a modification of human C3 for medical utility to abrogate the systemic damage caused by complement activation in PNH . This new complement treatment is expected to greatly improve the standard of care for PNH
